Collaborative efforts driving progress in pediatric acute myeloid leukemia

C. Michel Zwaan, Edward A. Kolb, Dirk Reinhardt, Jonas Abrahamsson, Souichi Adachi, Richard Aplenc, Eveline S J M De Bont, Barbara De Moerloose, Michael Dworzak, Brenda E S Gibson, Henrik Hasle, Guy Leverger, Franco Locatelli, Christine Ragu, Raul C. Ribeiro, Carmelo Rizzari, Jeffrey E. Rubnitz, Owen P. Smith, Lillian Sung, Daisuke TomizawaMarry M. Van Den Heuvel-Eibrink, Ursula Creutzig, Gertjan J L Kaspers

Research output: Contribution to journalArticlepeer-review


Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, with an incidence of approximately seven occurrences per 1 million children annually, national and international collaborative efforts have evolved. This overview describes these efforts and includes a summary of the history and contributions of each of the main collaborative pediatric AML groups worldwide. The focus is on translational and clinical research, which includes past, current, and future clinical trials. Separate sections concern acute promyelocytic leukemia, myeloid leukemia of Down syndrome, and relapsed AML. A plethora of novel antileukemic agents that have emerged, including new classes of drugs, are summarized as well. Finally, an important aspect of the treatment of pediatric AML - supportive care - and late effects are discussed. The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.

Original languageEnglish
Pages (from-to)2949-2962
Number of pages14
JournalJournal of Clinical Oncology
Issue number27
Publication statusPublished - Sep 20 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Collaborative efforts driving progress in pediatric acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this